COMP <GO>
PCVX vs IBRX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Vaxcyte Inc. (NASDAQ) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: PCVX 7
— IBRX 4
■ METRIC PARITY
LAST: $62.03 (-0.93%) • MKT CAP: $9.76B
options-implied-move
—
LAST: $8.29 (-5.15%) • MKT CAP: $8.79B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | -27.30% | -0.30 | IBRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | -3.33% | -3.46 | IBRX | /fcf-yield <GO> |
| Operating Margin | -33.50% | -60.00% | +26.50 | PCVX | /operating-margins <GO> |
| Net Profit Margin | 0.00% | -60.00% | +60.00 | PCVX | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 180.00% | -160.20 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 0.45 | +17.66 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | IBRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 44.3 | +4.40 | PCVX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.05 | +0.02 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 29.0x | -6.00 | PCVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.76B | $8.79B | $976.8M | PCVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | IBRX REV | PCVX GROSS % | IBRX GROSS % | PCVX FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $113.3M | — | 99.3% | -$669.3M | -$308.8M |
| FY 2024 | $0 | $14.7M | — | 100.0% | -$475.1M | -$398.1M |
| FY 2023 | $0 | $622.0K | — | — | -$296.8M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
IBRX // BETA 1.05